This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Discussing the potential of Centanafadine, a medication currently in development by Otsuka that for the treatment of ADHD
Ticker(s): OTSKYWho's the expert?
Institution: Johns Hopkins
- Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine & Director of the Adult Attention Deficit Disorder Center of Maryland
- 31 years in clinical practice with adult ADHD age 15 and older, mood/anxiety disorders and currently treats 500+ patients.
- Previously has been a Principal Investigator for multi-site Phase II and III drug trials for the treatment of adult ADHD and Major Depression. Dr. Goodman is the lead author on the largest adult ADHD trial published and the lead author on the largest survey assessment of physician clinical practice for adults with ADHD. He has published articles in peer-reviewed journals, authored four book chapters and The Black Book of ADHD.
Interview GoalThis call will focus on the results rom the the trials on Centanafadine, a medication currently in development by Otsuka for the treatment of ADHD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
